Charles River Laboratories International (CRL) Capital Expenditures (2009 - 2025)

Charles River Laboratories International (CRL) has reported Capital Expenditures for 17 consecutive years, with $89.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Capital Expenditures rose 17.63% year-over-year to $89.0 million; the TTM figure through Dec 2025 stood at $219.2 million (down 5.93% YoY), while the FY2025 annual figure was $219.2 million, down 5.93% from the prior year.
• Capital Expenditures came in at $89.0 million for Q4 2025 at Charles River Laboratories International, up from $35.6 million in the prior quarter.
• The five-year high for Capital Expenditures was $106.9 million in Q2 2023, with the low at $28.0 million in Q1 2021.
• Average Capital Expenditures over 5 years is $66.2 million, with a median of $69.9 million recorded in 2022.
• Across the five-year window, Capital Expenditures jumped 187.06% in 2022 and tumbled 41.4% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $98.8 million in 2021, then decreased by 9.87% to $89.0 million in 2022, then dropped by 12.02% to $78.3 million in 2023, then retreated by 3.46% to $75.6 million in 2024, then gained by 17.63% to $89.0 million in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $89.0 million, $35.6 million, and $35.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.